Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;7(2):240-7.
doi: 10.2215/CJN.05610611. Epub 2011 Dec 1.

Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease

JulieAnne G McGregor  1 , Susan L Hogan, Yichun Hu, Caroline E Jennette, Ronald J Falk, Patrick H Nachman
Affiliations

Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease

JulieAnne G McGregor et al. Clin J Am Soc Nephrol. 2012 Feb.

Abstract

Background and objectives: The optimal course of glucocorticoid therapy in anti-neutrophil cytoplasmic autoantibody (ANCA) disease is unknown. This cohort study evaluates effects of glucocorticoid therapy duration on patient outcomes and adverse events.

Design, setting, participants, & measurements: This study assessed 147 patients diagnosed between January 1, 2000 and January 1, 2009 who were treated with glucocorticoids and cyclophosphamide. Patients with end stage kidney disease at presentation, treatment resistance, or who had died within 6 months were excluded. Patients were divided into three groups: 0, 5, or >5 mg prednisone daily at 6 months after therapy initiation. The latter two groups were combined for assessment of adverse events. Wilcoxon rank sum, Kruskal-Wallis, or Fisher's exact tests were used for between-group comparisons. Time to relapse was evaluated by the Kaplan-Meier method with log-rank test for comparison.

Results: There were no differences between groups in ANCA specificity, serum creatinine, frequency of risk factors for relapse, or length of therapy with immunosuppressants. Length of glucocorticoid therapy had no impact on time to relapse (hazard ratio, 0.69 [95% confidence interval (CI), 0.23-2.02]; 1.01, [95% CI, 0.57-1.81] for the 5-mg and >5-mg groups, respectively), relapse-free survival, end stage kidney disease, or death. Patients receiving glucocorticoids beyond 6 months had significantly higher incidence of infections (0.64 infections per person-year versus 0.39, P<0.0001) and a marginally significant higher frequency of new-onset diabetes mellitus (odds ratio, 2.03; 95% CI, 0.94-4.38).

Conclusions: Glucocorticoid therapy beyond 6 months is associated with a significantly greater risk of infections but not a significantly decreased risk of relapse.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Derivation of the Glomerular Disease Collaborative Network Anti-Neutrophil Cytoplasmic Antibody Disease Cohort (GDCN ANCA). *Some patients met more than one exclusion criterion.
Figure 2.
Figure 2.
Relapse-free survival for the three groups of patients based on prednisone use at 6 months.
See this image and copyright information in PMC

References

    1. Fauci AS, Wolff SM, Johnson JS: Effect of cyclophosphamide upon the immune response in Wegener’s granulomatosis. N Engl J Med 285: 1493–1496, 1971 - PubMed
    1. Novack SN, Pearson CM: Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 284: 938–942, 1971 - PubMed
    1. Nachman PH, Hogan SL, Jennette JC, Falk RJ: Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7: 33–39, 1996 - PubMed
    1. Holle JU, Gross WL, Latza U, Nölle B, Ambrosch P, Heller M, Fertmann R, Reinhold-Keller E: Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63: 257–266, 2011 - PubMed
    1. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH: Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143: 621–631, 2005 - PubMed

Publication types

MeSH terms